AKUMS - IntraDay Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

IntraDay Trade Rating: 3.3

📊 Intraday Trading Analysis for AKUMS (Akums Drugs & Pharmaceuticals Ltd.)

AKUMS offers a moderate intraday setup, with strong earnings growth and solid fundamentals, but weak technical momentum and subdued volume. The stock is trading just below its 50-DMA, which could act as a pivot level if buying interest picks up during the session.

🔍 Key Technical & Fundamental Insights

⚖️ Technical Snapshot

RSI at 46.4: Neutral zone — lacks momentum but not oversold.

MACD at -6.93: Bearish crossover — short-term weakness.

Current Price ₹545 < DMA50 ₹551 and DMA200 ₹596: Below key averages — trend under pressure.

Volume Today (1.11L) < Avg Vol 1Wk (1.26L): Slightly below average — low conviction.

52w Index at 18.2%: Near yearly lows — poor relative strength.

✅ Fundamental Strength

ROCE 16.2% & ROE 17.2%: Solid capital efficiency.

EPS ₹21.5 vs. P/E 26.6: Reasonably valued compared to industry PE of 34.0.

PEG Ratio 0.54: Undervalued relative to growth.

Debt-to-Equity 0.03: Virtually debt-free — low financial risk.

PAT Qtr ₹142 Cr vs. Prev Qtr ₹61.8 Cr: Strong profit growth.

Qtr Profit Var +458%: Exceptional earnings momentum.

DII Holding Change +1.46%: Positive domestic sentiment.

❌ Sentiment Risks

FII Holding Change -1.53%: Foreign selling — sentiment mildly negative.

Price far below 52-week high ₹1,176: Long-term weakness.

🛒 Optimal Buy Price for Intraday

Buy Zone: ₹538–₹542 Entry only if RSI climbs above 48 and MACD flattens or turns positive with volume exceeding 1.3L.

🎯 Exit Strategy

Profit-Taking Levels

Target 1: ₹555 — near 50-DMA resistance

Target 2: ₹565 — short-term breakout zone

Stop-Loss / Loss Protection

Stop-Loss: ₹530 — below recent support and psychological level

📈 If You Already Hold the Stock Today

Exit on Weakness

RSI drops below 44 or MACD widens negatively

Price fails to hold above ₹540 post 12:30 PM IST

Volume Watch

If volume fades below 1L and price stalls, consider exiting near ₹553

Trailing Stop Strategy

If price crosses ₹558, trail stop-loss upward by ₹6–₹8 increments

Would you like a comparison with other mid-cap pharma stocks showing stronger intraday momentum and technical setups?

Edit in a page